Using HER2 PET imaging to improve treatment for bladder cancer
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11061006
This study is looking at how a special imaging technique can help doctors see differences in a protein called HER2 in bladder cancer, which might help them figure out the best treatments for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11061006 on ClinicalTrials.gov |
What this research studies
This research investigates how HER2 PET imaging can help assess the variability of HER2 expression in bladder cancer and predict how well patients will respond to targeted therapies. By examining both primary and metastatic tumors, the study aims to identify differences in HER2 expression that could influence treatment outcomes. The approach involves using advanced imaging techniques to visualize HER2 levels, which may guide personalized treatment plans for patients with urothelial carcinoma. Ultimately, the goal is to enhance the effectiveness of HER2-targeted antibody-drug conjugates in treating this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic urothelial carcinoma who exhibit HER2 expression.
Not a fit: Patients with non-metastatic bladder cancer or those without HER2 expression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with metastatic bladder cancer.
How similar studies have performed: Other research has shown promising results with HER2-targeted therapies in similar cancer types, indicating potential for success in this novel application.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: IYER, GOPA — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: IYER, GOPA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.